If participant is found to be eligible to take part in this study, participant will receive daratumumab by vein over about 4 hours on Days 1, 8, 15, and 22 of Cycles 1 and 2, Days 1 and 15 of Cycles 3-6, and then on Day 1 of Cycles 7 and beyond. Participant's first dose of daratumumab will be given over about 7 hours.